-transparent.png){kind=logo}
1. The pharmacokinetics of ethylmorphine after administration of a single dose of the cough mixture Cosylan were investigated in 10 healthy subjects. 2. The median urinary recovery of ethylmorphine and measured metabolites was 77% over 48 h. The median tmax of unchanged ethylmorphine was 45 min, and the terminal elimination t1/2 was 2 h. Ethylmorphine-6-glucuronide was found to be the major metabolite. 3. Two subjects had significantly lower urinary recovery (0.48 h) of morphine and morphine-glucuronides than the remainder. Furthermore, these two had urinary metabolic ratios (MRO) and partial metabolic clearances (CLmO) for O-deethylation of ethylmorphine tentatively classifying them phenotypically as poor metabolisers of the debrisoquine/sparteine type. 4. Genotyping for cytochrome P450 (CYP) 2D6 alleles revealed five homozygote (wt/wt) and five heterozygote subjects. Two subjects phenotypically classified as poor metabolisers were genotypically CYP2D6A/wt and CYP2D6D/wt, respectively. 5. Serum and urine samples taken more than 8 and 24 h after administration of ethyl-morphine respectively, contained morphine and morphine-glucuronides, but no ethylmorphine, ethylmorphine-6-glucuronide or (serum only) norethylmorphine. Norethylmorphine could be detected after hydrolysis of urine samples in all subjects. The urinary recovery of the active metabolites morphine and morphine-6-glucuronide after administration of ethylmorphine varied by a factor of 9 between individuals. 6. The wide variation in recovery of morphine and morphine-glucuronides after oral administration of ethylmorphine could not be explained simply by a difference in CYP2D6 genotype. Constitutional variation in other enzymatic pathways involved in ethylmorphine metabolism is probably crucial. Ratios of morphine to parent drug cannot be used to distinguish the source of morphine after administration of ethylmorphine. Norethylmorphine should be included in urine assays for opiates in forensic toxicology, and no firm conclusions about the source of morphine are possible based on serum samples obtained more than 24 h after drug administration.
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
January 1997,
Xenobiotica; the fate of foreign compounds in biological systems,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
May 1982,
British journal of clinical pharmacology,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
April 1992,
British journal of clinical pharmacology,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
January 1988,
International journal of clinical pharmacology research,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
August 2021,
Drug metabolism and disposition: the biological fate of chemicals,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
December 1990,
International journal of clinical pharmacology, therapy, and toxicology,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
January 1975,
The Journal of clinical endocrinology and metabolism,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
January 2002,
Clinical pharmacokinetics,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
January 1991,
European journal of clinical pharmacology,
T A Aasmundstad, and
B Q Xu, and
I Johansson, and
A Ripel, and
A Bjørneboe, and
A S Christophersen, and
E Bodd, and
J Mørland
August 1996,
International journal of clinical pharmacology and therapeutics,
